Laura Cooney

Dr. Laura Cooney

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
ESElliott SoRelle
Elliott SoRelle
EHEllora Haukenfrers
Ellora Haukenfrers
GHGillian Q. Horn
Gillian Q. Horn
VJVaibhav Jain
Vaibhav Jain
JGJames Giarraputo
James Giarraputo
MLMicah Luftig
Micah Luftig
Epstein-Barr virus (EBV) infection precedes multiple sclerosis (MS) onset and plays a poorly understood etiologic role. To investigate possible viral pathogenesis, we analyzed single-cell expression in peripheral B cells from people with early MS collected longitudinally during the Immune Tolerance Network STAyCIS Trial. Expression profiles were compared with single-cell RNA-Seq (scRNA-Seq) from in vitro EBV models, autoimmune disorders, chronic infectious diseases, and healthy controls. Analyses focused on CD19 + CD20 + CD21 lo CD11c + T-bet + atypical B cells (ABCs). ABCs were significantly enriched in early MS PBMCs versus healthy controls by scRNA-Seq and flow cytometry, establishing ABC expansion as a clinical feature. EBV-associated ABC expression, including CXCR3, programmed cell death ligand 1 (PD-L1), and PD-L2, was enriched in early MS; however, direct EBV infection of ABCs was not detected. Early MS ABCs exhibited significantly upregulated inflammatory cytokine mRNAs ( CXCL8 , IL18 , VEGFA ). Further, de novo EBV-infected B cells secreted IL-8 and VEGF. MS activity stratification revealed rare, distinctive inflammatory ABCs significantly underrepresented in individuals with no evidence of activity long-term versus people with additional relapsing-remitting MS activity at the primary endpoint. Moreover, CXCR3 + ABCs increased after baseline diagnosis and were significantly enriched in people with disease exacerbation during the study. Thus, ABC expansion and inflammatory responses correlate to early MS activity, possibly as a bystander response to EBV.

27 August 2022 in Journal of Immunological Methods
Verified
Journal Article
Open access
IMIna Mexhitaj
Ina Mexhitaj
NLNoha Lim
Noha Lim
JFJose I. Fernandez-Velasco
Jose I. Fernandez-Velasco
TZTobias Zrzavy
Tobias Zrzavy
KHKristina M. Harris
Kristina M. Harris
LCLaura Cooney
Laura Cooney
Analysis of cerebrospinal fluid (CSF) represents a valuable window into the pathogenesis of neuroinflammatory diseases, such as multiple sclerosis (MS). However, analysis of the cellular fraction of CSF is often neglected because CSF cells die rapidly ex vivo. Immunophenotyping of CSF cells in multicenter clinical trials requires sample preservation and shipping to a centralized lab. Yet, there is no consensus on the best method to preserve intact CSF cells and no detailed evaluation of subset-specific cell loss. We used flow cytometry to compare major leukocyte populations in fresh CSF (processed within 2 h) to cells fixed for 48 h with TransFix-EDTA® or cryopreserved and thawed after 96 h. We observed a statistically significant loss of total mononuclear cells, total T cells, CD3+ CD8- T cells, and CD3+ CD8+ T cells after cryopreservation compared to fresh or fixed (p < 0.001), with no significant difference between fresh and fixed. Thus, our results demonstrate that TransFix-EDTA® was superior to cryopreservation for preserving intact CSF T cells. Surprisingly, neither cryopreservation nor fixation had a significant effect on recovery of low frequency cell subsets in CSF, including B cells, NK cells, NKT-like cells, CD14+ monocytes, or CD123+ DCs, versus fresh CSF. To determine the effect of prolonged fixation on cell recovery, we analyzed major CSF cell subsets by flow cytometry after 24, 48, or 72 h of fixation with TransFix-EDTA®. We observed a consistent and progressive loss in the absolute counts of all subsets over time, although this effect was not statistically significant. We conclude that for immunophenotyping of major CSF cell subsets by flow cytometry, fixation with TransFix-EDTA®, shipment to a central lab, and analysis within 48 h is a feasible method to ensure stability of both absolute cell number and relative frequency. This method is a valuable alternative to fresh CSF analysis and can be implemented in multicenter clinical trials.

29 October 2023 in Clinical Immunology
Verified
Journal Article
Open access
ANAditi Narsale
Aditi Narsale
FAFrancisco Almanza
Francisco Almanza
TTTheo Tran
Theo Tran
BLBreanna Lam
Breanna Lam
DSDavid Seo
David Seo
JDJoanna D. Davies
Joanna D. Davies
Soon after diagnosis with type 1 diabetes (T1D), many patients experience a period of partial remission. A longer partial remission is associated with a better response to treatment, but the mechanism is not known. The frequency of CD4+CD25+CD127hi (127-hi) cells, a cell subset with an anti-inflammatory Th2 bias, correlates positively with length of partial remission. The purpose of this study was to further characterize the nature of the Th2 bias in 127-hi cells. Single cell RNA sequencing paired with TCR sequencing of sorted 127-hi memory cells identifies clonally expanded Th2 clusters in 127-hi cells from T1D, but not from healthy donors. The Th2 clusters express GATA3, GATA3-AS1, PTGDR2, IL17RB, IL4R and IL9R. The existence of 127-hi Th2 cell clonal expansion in T1D suggests that disease factors may induce clonal expansion of 127-hi Th2 cells that prolong partial remission and delay disease progression.

1 January 2025 in The Journal of Immunology
Verified
Journal Article
Open access
LHLauren E Higdon
Lauren E Higdon
LCLaura Cooney
Laura Cooney
ESElisavet Serti
Elisavet Serti
DSDuangchan Suwannasaen
Duangchan Suwannasaen
VMVirginia S Muir
Virginia S Muir
SLS Alice Long
S Alice Long
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity. We characterized T cell responses by flow cytometry and identified an exhausted-like population of CD2low CD4 effector memory T cells coexpressing TIGIT and PD1 that expanded by 11 wk after the start of treatment. This population was not entirely spared from alefacept-mediated depletion in vivo or in vitro but recovered through homeostatic proliferation of CD2low cells in vivo. Proliferation of TIGIT+PD1+ effector memory CD4 T cells increased with treatment, with a concomitant reduction of proinflammatory cytokine production. The persistent increase of TIGIT+PD1+ effector memory CD4 T cells was specific to alefacept treatment; 2 other T cell depleting therapies, teplizumab and anti-thymocyte globulin, induced only a transient increase in this CD4 population. Our data suggest that the expanding TIGIT+PD1+ effector memory CD4 T cell population represents a promising biomarker of early treatment effects of alefacept. The nondepleting effects on proliferation and cytokine production also suggest agonistic activity by this CD2 targeted therapy.

13 September 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
MGMikel Gurrea-Rubio
Mikel Gurrea-Rubio
LCLaura Cooney
Laura Cooney
KMKohei Maeda
Kohei Maeda
PCPhillip L. Campbell
Phillip L. Campbell
QWQi Wu
Qi Wu
DFDavid Fox
David Fox
Objective: Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods: In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months one, three, and six. Flow cytometry quantified CD4+CD319+ and CD8+CD319+ T cells, cytotoxic and activation markers, and stimulated intracellular interleukin‐4 (IL‐4), IL‐17A, and interferon‐γ (IFN‐γ). Analyses compared abatacept‐treated molecular endotypes with placebo and related immune changes to modified Rodnan skin score (mRSS) change. Skin single‐cell RNA sequencing included five healthy controls and eight patients with SSc. Results: At baseline, CD319+ T cells showed greater cytokine production, activation, and granzyme and perforin expression than CD319− T cells in 60 evaluable participants ( P < 0.001 to P < 0.0001). Abatacept reduced CD4+CD319+ and CD8+CD319+ T cell frequencies at month six; placebo did not. Effects were strongest in patients in the fibroproliferative group, in whom CD8+CD319+ T cells decreased versus placebo (n = 7 versus n = 36; P = 0.0377). In this endotype, abatacept reduced IL‐4 in CD4+CD319+ and CD8+CD319+ T cells at month three ( P = 0.0468 and P = 0.0287) and IL‐17A in CD8+CD319+ T cells at month six ( P = 0.0004), whereas IFN‐γ was unchanged. Reduction in CD4+CD319+ T cells correlated with mRSS improvement in abatacept‐treated patients (r = 0.5297, P = 0.0423). Skin single‐cell RNA sequencing showed increased SLAMF7 expression in SSc T cells ( P = 0.017), enriched within cytotoxic subsets. Conclusion: CD319+ T cells represent highly differentiated, activated cytotoxic effector populations in SSc. Abatacept selectively modulates these cells and suppresses associated profibrotic and proinflammatory cytokines, particularly in the fibroproliferative subtype, in which CD319+ T cell reductions correlate with clinical improvement. image

17 August 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
MGMikel Gurrea-Rubio
Mikel Gurrea-Rubio
SSSophie Julia Sloan
Sophie Julia Sloan
ACAditya Chada
Aditya Chada
CACamila I. Amarista
Camila I. Amarista
KMKohei Maeda
Kohei Maeda
DFDavid Fox
David Fox
Triple-negative breast cancer (TNBC) is associated with recurrence, metastasis, and limited durable responses to immunotherapy, in part due to persistence of breast cancer stem cells (BCSCs). We investigated whether CD6-directed immunotherapy with the monoclonal antibody UMCD6 enhances immune-mediated killing and alters function of BCSC in stem cell-enriched TNBC models. The SUM-149 and SUM-159 cell lines were analyzed for CD6 ligand expression, cocultured with human peripheral blood mononuclear cells (PBMCs) treated with UMCD6, pembrolizumab, or isotype control, and assessed by live-cell cytotoxicity imaging, flow cytometry, soft agar colony formation, and extreme limiting dilution sphere assays. Both TNBC lines co-expressed the CD6 ligands CD44, CD166/ALCAM, and CD318/CDCP1. UMCD6 significantly increased PBMC-mediated apoptosis and reduced tumor cell survival in both models, with greater activity than pembrolizumab under these in vitro conditions. In surviving SUM-159 cells, UMCD6 reduced the ALDH+ population wit×hout significantly altering CD44+CD24− frequency, indicating preferential effects on a distinct stem-like compartment. Functionally, UMCD6 decreased anchorage-independent colony formation and reduced sphere-forming frequency from 1/33.6 to 1/68.3 cells (p = 0.0186). These findings identify the CD6 ligand axis as a therapeutic vulnerability in BCSC-enriched TNBC and support further preclinical evaluation of CD6-directed immunotherapy as a strategy to enhance antitumor immunity while limiting tumor-initiating capacity.